Videos

Agentic AI speeds oncology trial screening by synthesizing records and ranking candidates, while clinicians keep final eligibility and consent decisions.

Laila Alkhouli, MD, discusses the importance of early detection of chronic graft-vs-host-disease and why standardizing screening is crucial.

Agentic AI taps electronic medical records to flag timely oncology trial candidates, fit workflow, cut clinician burden, and boost community practice enrollment.

Andrew Evens, DO, and Joanna Rhodes, MD, on CLL's transformation, CAR T vs bispecifics, Hodgkin survivorship, and delivering world-class lymphoma care across New Jersey.

Agentic AI in oncology distills evidence, molecular data, and guidelines to aid therapy decisions, promising smarter, context-aware cancer care.

David Savage, MD, PhD, discusses the greater significance of the PFS benefit observed in a trial of darovasertib plus crizotinib in patients with HLA-A*02:01–negative uveal melanoma.

UCSF's Scarlett Lin Gomez, PhD, MPH, discusses how the clinician-researcher partnership shapes future work.

David Savage, MD, PhD, discusses the significance of abemaciclib's PFS benefit in liposarcoma and how he approaches getting patients access to it.

Scarlett Lin Gomez, PhD, MPH, of UCSF, explains why Asian American women's breast cancer survival advantage persists after adjusting for clinical and lifestyle factors.

Cox and Abbadi outline next steps for BDNF/TrkB-targeted therapy, including translating the approach to high-grade serous ovarian cancer.

Hearn Jay Cho, MD, PhD, discusses the ongoing role of the CoMMpass dataset in researching immunotherapy and targeted therapy in high-risk multiple myeloma.

Maureen Cox, PhD, and Jumana Abbadi, MD, explain how macrophage-derived BDNF drives sensory nerve growth into triple-negative breast tumors, a potential drug target.

Learn how community oncologists deliver bispecific antibodies safely: step-up dosing, CRS prevention, infection support, and patient counseling.

Hearn Jay Cho, MD, PhD, of the Multiple Myeloma Research Foundation, looks back on 15 years of the groundbreaking CoMMpass genomic study.

Dr. Monty Pal concludes the program by discussing how the treatment landscape for advanced renal cell carcinoma (RCC) may evolve as new clinical evidence emerges.

Experts weigh response speed, survival and quality of life to choose first-line IO-TKI or dual immunotherapy for metastatic clear cell RCC.

Sagar Lonial, MD, discusses the importance of baseline MRD assessment to aid in using sustained MRD negativity for eventual discontinuation of lenalidomide in newly diagnosed multiple myeloma.

City of Hope's Dr Ravi Salgia urges fellow oncologists to refer eligible patients to a new national trial predicting immunotherapy success in NSCLC.

City of Hope's Dr Ravi Salgia on what it would truly take to cure stage IV non–small cell lung cancer and where oncology is headed next in the years ahead.

Sagar Lonial, MD, discusses why to take an individualized approach despite the trial's findings supporting discontinuation of lenalidomide at 2 years.

ASCO 2026 data show ePRO remote symptom monitoring cuts ER visits and costs, enabling faster toxicity detection and safer community cancer care.

OncoPRO unites oncology practices to streamline ePRO remote symptom monitoring, improving enrollment, workflow integration, and change management through shared implementation strategies.

ASCO 2026 data show ePRO symptom tracking keeps cancer patients on therapy longer, cuts hospitalizations and costs, and may boost survival.

City of Hope's Dr Ravi Salgia explains a new national trial using biomarkers to predict immunotherapy success in advanced non–small cell lung cancer.

Real-world ASCO 2026 data show ePRO-based remote monitoring helps catch metastatic cancer treatment symptoms earlier, improving toxicity control and reducing hospitalizations.

Patrick Borgen, MD, built Brooklyn's breast cancer program from 47 patients to 8,000. Now he and Joshua Feinberg, MD discuss what surgery looks like next.

Dr. Monty Pal concludes his discussion on treatment sequencing in advanced renal cell carcinoma (RCC) by summarizing how he applies current guideline recommendations alongside individualized clinical decision making in routine practice.

Dr. Monty Pal reviews emerging clinical evidence evaluating belzutifan-based treatment strategies in advanced renal cell carcinoma (RCC), with particular focus on the LITESPARK-011 trial comparing lenvatinib plus belzutifan with cabozantinib.

ASCO 2026 real-world data tie GLP-1 drugs to longer cancer survival, but oncology EHRs miss timing and duration—heres why it matters.

Mark Agulnik, MD, discusses the trend away from surgery and toward targeted treatment of progressive desmoid tumors, and how sequencing is the next major question.